Fluid therapy with l-lactate and/or pyruvate anions

a technology of pyruvate anions and fluoride, which is applied in the field of human fluoride therapy, can solve the problems of death, worsening of cerebral edema, and d-form has now been discovered to cause adverse and toxic effects,

Inactive Publication Date: 2005-03-17
BTG INT LTD
View PDF8 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

More particularly, this invention is directed to improved methods and optionally stable fluids for conventional administration to humans such as, (a) oral ingestion of an aqueous solution containing at least one of such anions, or a mixture of such anions, (b) parenteral therapy involving, for example, the intravenous administration of an aqueous solution containing at least one of such anions, or a mixture thereof, (c) dialysis therapy (hemo or peritoneal) using aqueous solutions containing at least one of such anions, (d) dialysis therapy (hemo or peritoneal) where acetic acid is replaced with at least one acid of the group consisting of 1-lactate, pyruvate, d-betahydroxybutyrate or acetoacetic acid, preferably 1-lactate, and / or (e) irrigation therapy.
One presently preferred such anion comprises 1-lactate. Thus, surprisingly, encephalopathy, metabolic bone disease, and many other complications are not only completely avoided by using 1-lactate (or one of the other metabolite anions herein identified and used in the practice of this invention) in place of racemic d-1-lactate, but also the substitution of, for example, 1-lactate for d-1-lactate, in solutions employed in fluid therapy, does not cause any change in the heretofore known beneficial physiological or pharmacological effectiveness of such fluids.

Problems solved by technology

Thus, the d- form has now been discovered to cause adverse and toxic effects when administered to mammals.
With continued administration, coma develops, the cerebral edema worsens and death ensues.
Thirdly, it is used as the counter ion in peritoneal dialysis solutions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fluid therapy with l-lactate and/or pyruvate anions

Examples

Experimental program
Comparison scheme
Effect test

embodiments

The following examples are merely illustrative of the present invention and are not intended as a limitation upon the scope thereof.

examples 1-4

The following Table III illustrates particular solutions of this invention:

TABLE III(Values are in mnMoles / Liter)Ex. No.ComponentClass IClass IIClass III1l-lactate(1)1000Na+10002pyruvate(2)1000Na+10003l-lactate(3)900pyruvate100Na+10004l-lactic acid5

Table III footnotes:

(1)For treatment of acidosis see Merck Handbook, p 1866 12th edition.

(2)For treatment of acidosis when severe reduction of [NAD+] / [NADH] is present (see USSN 748,232).

(3)For treatment of acidosis when redox balance is desired (see USSN 748,232).

(4)For use as an additive to a bicarbonate containing solution (see USSN 748,232).

examples 5-12

Illustrative examples of various physiological abnormalities which are treatable by using various starting solutions of the present invention are shown in Table IV below:

TABLE IVExemplary UseagesCondition WhereUseful andFluid CompositionRoute ofsolution commonCation(s)Anion(s)Administration,namein mMoles / literand Dose5. DehydrationNa+130Cl−109Parenteral,(L-lactatedK+3l-lac-28500 ml to 3tate−liters per dayRingers) (1)Ca2+1.5depending onseverity andcause6. PeritonealNa+141Cl−101Intraperitoneal,DialysisCa2+1.75l-lac-454 to 8, 2 litertate−bags per day(Dianeal (2) w / Mg2+0.751.5% Dextrose,(also dextrose 83)Travenol) (3)7. MetabolicNa+156.1l-lac-156.1Parenteral orAcidosistateoral, 10 ml to(Isotonic so-1 L depending ondium l-lactatesize of patientsolution) (4)8. CardiacNa+145Cl−115IntracoronaryReperfusionCa2+0.5HCO3−25infusion afterFluid(5)Mg2+0.75pyru-11.5cardiac arrestvate−K+4(also glucose 10 andCO2 1.2)9. DehydrationNa+120.2Cl−104.7Parenteral orand PotassiumK+36.2l-lac-51.7oral (8).Lo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
water contentaaaaaaaaaa
concentrationaaaaaaaaaa
solutionaaaaaaaaaa
Login to view more

Abstract

Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized and cellular cofactor ratios are normalized in a manner which decreases toxicity over prior art solutions.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention lies in the field of fluid therapy in humans, and more particularly in the field of aqueous solutions for parenteral, oral, dialysis, and irrigation therapy which employ at least one of 1-lactate anions, pyruvate anions, d-betahydroxybutyrate anions, acetoacetate anions, or mixtures thereof in combination with selected cations. 2. Prior Art Previously, I have provided improved electrolyte solutions for in vivo and in vitro usage which contain 1-lactate and pyruvate anions, and / or d-betahydroxybutyrate and acetoacetate anions in respective defined ratios in combination with defined Na:Cl ratios; see my copending U.S. patent applications Serial Nos. 748,232 and 747,792, both filed Jun. 24, 1985, and also my copending U.S. patent application Serial Nos. 747,858 and 748,184, also filed on such date. However, it is now appreciated that the benefits of using 1-lactate, pyruvate, d-betahydroxybutyrate, and / or acetoace...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/19A61K33/06A61K33/10A61K33/14A61M1/16A61M1/28C12N5/00
CPCA61K31/19A61K33/06A61K33/10A61K33/14A61M1/1654A61M1/287C12N2500/12C12N5/0018A61K33/00A61K2300/00
Inventor VEECH, RICHARD L.
Owner BTG INT LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap